会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS
    • 用于治疗CFTR -MEDDITED病症的药物组合物
    • WO2013185112A8
    • 2014-08-14
    • PCT/US2013044838
    • 2013-06-07
    • VERTEX PHARMA
    • VAN GOOR FREDRICK F
    • A61K31/404A61K31/44A61K31/47A61P43/00
    • C07D215/56A61K9/08A61K9/1617A61K9/1652A61K9/2018A61K9/2054A61K9/2077A61K9/4858A61K9/4866A61K31/404A61K31/443A61K31/47A61K45/06A61K47/10A61K47/26A61K47/32A61K47/38C07D405/12A61K2300/00
    • The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound &iacgr; in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxoI- 5-yl)cyclopropanecarboxamide)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3- dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)- 1H-indol-5-yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to solid forms and formulations of Compound 2 or Compound 3 in combination with Compound 1, and pharmaceutical compositions thereof, for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    • 本发明涉及使用N- [2,4-双(1,1-二甲基乙基)-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺(化合物1) 及其药物组合物,用于治疗具有特定遗传突变的患者中CFTR介导的疾病,特别是囊性纤维化。 本发明还涉及化合物的用途; 与3-(6-(1-(2,2-二氟苯并[d] [1,3]二氧代-5-基)环丙烷甲酰胺)-3-甲基吡啶-2-基)苯甲酸(化合物2)和 化合物1与(S)-1-(2,2-二氟苯并[d] [1,3]二氧杂环戊烯-5-基)-N-(1-(2,3-二羟基丙基)-6-氟-2 - (1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺(化合物3),用于在具有特定遗传突变的患者中治疗CFTR介导的疾病,特别是囊性纤维化。 本发明还涉及化合物2或化合物3与化合物1组合的固体形式和制剂及其药物组合物,用于治疗具有特定遗传突变的患者的CFTR介导的疾病,特别是囊性纤维化。